Endo International plc

Endo International plc
Public
Traded as
Industry Pharmaceutical
Headquarters Dublin, Ireland and Malvern, Pennsylvania, U.S.
Revenue US$ 3.7 billion (2017)
Website endo.com

Endo International plc is a generics and specialty branded pharmaceutical company. It was created as a result of a management buyout from DuPont Merck in 1997 led by Carol Ammon.[1]

History and Acquisitions

In 2009, Endo bought Indevus Pharmaceuticals to diversify into endocrinology and oncology.[2] The company entered the male hypogonadism market later in 2010 with Fortesta 2% gel.[2]

In November 2013, Endo agreed to purchase Paladin Labs Inc for about $1.6 billion to gain access to the Canadian market as well as expand into emerging markets.[3][4]

In October 2014, Endo said it would buy Auxilium Pharmaceuticals for $2.6 billion,[5] along with its testosterone replacement therapy products.[6]

In 2015, Endo acquired the specialty generics and sterile injectables company Par Pharmaceutical for $8.05 billion.[7]

In 2018, Endo settled over 1,200 lawsuits related to its testosterone replacement therapy, Testim, and its undisclosed side effects.[6]

Acquisition attempts

In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million.[8] However, Teva prevailed in this acquisition with a substantially higher bid.[9]

Opioids

Endo is one of the companies named in lawsuits by the states of Ohio,[10] Missouri and Mississippi[11] as responsible for the US opioid epidemic. Its 10-K statement indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids.[12]

On June 8, 2017, the U.S. Food and Drug Administration (FDA) released a press statement in which it announced that it had requested Endo to withdraw its opioid drug, oxymorphone hydrochloride (Opana ER), from the market. It was the first time that the FDA had "taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse."[13]

See also

References

  1. Schneiderman, R.M. (9 April 2007). "Ammon Exits Endo". Forbes.
  2. 1 2 Associated Press (2009-01-06). "Endo to buy Indevus". The Boston Globe. Retrieved 2009-06-28.
  3. Rubin, Ben Fox (5 November 2013). "Endo Health to Buy Paladin Labs for $1.6 Billion". Wall Street Journal.
  4. "Endo Health to Buy Specialty Drug Maker for $1.6 Billion". New York Times Dealbook. November 5, 2013.
  5. "Endo Scores with $2.6B Offer for Auxilium, Which Ends QLT Deal | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN". GEN. October 9, 2014.
  6. 1 2 George, John (12 June 2018). "Endo executes master settlement agreement to resolve testosterone lawsuits". Philadelphia Business Journal. Retrieved 4 July 2018.
  7. Bray, Chad (18 May 2015). "Endo International to Pay $8.05 Billion for Par Pharmaceutical". The New York Times.
  8. "Endo to Purchase NuPahte for $150M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper). 34 (2). January 15, 2014. p. 10.
  9. "Teva Outbids Endo, Acquires NuPathe for $144M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper). 34 (4). February 15, 2014. p. 10.
  10. Dwyer, Colin (31 May 2017). "Ohio Sues 5 Major Drug Companies For 'Fueling Opioid Epidemic'". NPR Online.
  11. Raymond, Nate (21 Jun 2017). "Missouri sues opioid manufacturers, joining two other U.S. states". Reuters.
  12. "Eondo Pharmaceuticals, FORM 10-K". 31 Dec 2016.
  13. "FDA requests removal of Opana ER for risks related to abuse" (Press release). FDA. June 8, 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.